Please login to the form below

Not currently logged in
Email:
Password:

Merck u-turns on NDA for HIV drug

Merck & Co has said it will not submit a New Drug Application (NDA) to the US FDA for its HIV treatment, vicriviroc, at this time

Merck & Co has said it will not submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its HIV treatment, vicriviroc, at this time.

The company has made the announcement after the drug failed to meet the primary efficacy endpoint in two phase III trials in treatment-experienced HIV-infected patients. These particular trials involved a high percentage of patients who had three or more active drugs in their optimised background therapy regimen.

Vicriviroc was one of the drugs acquired by Merck when it purchased Schering-Plough for $41.4bn last year.

Merck will continue with current phase II trials investigating vicriviroc as a therapy in treatment-naïve HIV-infected patients. In addition, those treatment-experienced patients from the phase III who have responded well to treatment with the drug, will continue to have access to the medicine.

21st January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics